Solara Active Pharma Sciences Ltd reports consolidated PAT of Rs. 56.67 crore in Q2

Solara Active Pharma Sciences Ltd has reported financial results for the period ended September 30, 2020.

Financial Results (Q2 FY20-21) - QoQ Comparison

The company has reported total income of Rs.403.68 crores during the period ended September 30, 2020 as compared to Rs.353 crores during the period ended June 30, 2020.

The company has posted net profit / (loss) of Rs.56.67 crores for the period ended September 30, 2020 as against net profit / (loss) of Rs.42.28 crores for the period ended June 30, 2020.

The company has reported EPS of Rs.17.25 for the period ended September 30, 2020 as compared to Rs.14.74 for the period ended June 30, 2020.

Financials	Q2 FY20-21	Q1 FY20-21	% Change
Total Income	₹ 403.68 crs	₹ 353 crs	14.36%
Net Profit	₹ 56.67 crs	₹ 42.28 crs	34.04%
EPS	₹ 17.25	₹ 14.74	17.03%

Financial Results (Q2 FY20-21) - YoY Comparison

The company has reported total income of Rs.403.68 crores during the period ended September 30, 2020 as compared to Rs.356.08 crores during the period ended September 30, 2019.

The company has posted net profit / (loss) of Rs.56.67 crores for the period ended September 30, 2020 as against net profit / (loss) of Rs.28.77 crores for the period ended September 30, 2019.

The company has reported EPS of Rs.17.25 for the period ended September 30, 2020 as compared to Rs.11.16 for the period ended September 30, 2019.

Financials	Q2 FY20-21	Q2 FY19-20	% Change
Total Income	₹ 403.68 crs	₹ 356.08 crs	13.37%
Net Profit	₹ 56.67 crs	₹ 28.77 crs	96.98%
EPS	₹ 17.25	₹ 11.16	54.57%

Financial Results (6 months ended FY 20-21) - YoY Comparison

The company has reported total income of Rs.756.68 crores during the 6 months period ended September 30, 2020 as compared to Rs.690.61 crores during the 6 months period ended September 30, 2019.

The company has posted net profit / (loss) of Rs.95.88 crores for the 6 months period ended September 30, 2020 as against net profit / (loss) of Rs.55.27 crores for the 6 months period ended September 30, 2019.

The company has reported EPS of Rs.31.99 for the 6 months period ended September 30, 2020 as compared to Rs.21.38 for the 6 months period ended September 30, 2019.

Financials	Half-Year Ended FY20-21	Half-Year Ended FY19-20	% Change
Total Income	₹ 756.68 crs	₹ 690.61 crs	9.57%
Net Profit	₹ 95.88 crs	₹ 55.27 crs	73.48%
EPS	₹ 31.99	₹21.38	49.63%

Commenting on the performance, Bharath Sesha, the MD & CEO of the Company, remarked "Solara delivered a strong performance with yet another record quarter registering the highest ever Revenue, EBITDA and PAT for the company. The Company is thankful to all its employees for doing a tremendous job of execution in these difficult times while keeping in mind that health, hygiene and safety is paramount.

Our performance demonstrates the execution of Solara's core strategy led by strong customer partnerships, diverse product mix, engaged and committed employees, and a world-class compliance framework. We see continued positive demand for our products, and we are continuously gaining share of wallet at existing customers.

Based on the positive demand picture and the strong execution of our strategy we would like to revise our revenue growth guidance to 30%+ YoY from the earlier guidance of ~25-30% YoY for FY21 led primarily by the new capacities and increasing our EBITDA growth guidance to 40%+ YoY from the earlier guidance of ~25-30% YoY."

Shares of Solara Active Pharma Sciences Ltd was last trading in BSE at Rs.1125 as compared to the previous close of Rs. 1104.3. The total number of shares traded during the day was 6348 in over 1549 trades.

The stock hit an intraday high of Rs. 1310 and intraday low of 1103.2. The net turnover during the day was Rs. 7300971.

Source : Equity Bulls

Keywords